Quarterly ResultJul 29, 2026, 07:11 AM
uniQure Q2 Net Loss $81.1M; AMT-130 BLA on track for Q3 2026
AI Summary
uniQure N.V. reported a net loss of $81.1 million for Q2 2026, compared to $37.7 million in Q2 2025, on revenue of $5.8 million. The company announced that its Biologics License Application (BLA) for AMT-130 for Huntington’s disease remains on track for Q3 2026, following FDA alignment on the accelerated approval pathway. uniQure also strengthened its financial position with a $259 million follow-on offering, extending its cash runway into 2030. Early biological signals were observed for AMT-260 in epilepsy, while dosing for AMT-191 for Fabry disease was paused due to liver enzyme elevations.
Key Highlights
- AMT-130 BLA submission for Huntington’s disease on track for Q3 2026.
- Topline four-year data from AMT-130 Phase I/II study expected in September 2026.
- Completed $259 million follow-on offering, extending cash runway into 2030.
- Reported Q2 2026 net loss of $81.1 million, up from $37.7 million in Q2 2025.
- Q2 2026 revenue increased to $5.8 million from $5.3 million year-over-year.
- Cash, cash equivalents, and current investment securities totaled $810.3 million.
- R&D expenses decreased to $34.0 million from $35.4 million year-over-year.
- SG&A expenses increased to $17.4 million from $13.5 million year-over-year.
Price Impact
More from QURE